Geriatric Assessments in Senior Adults With Multiple Myeloma
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 65 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2012 |
| End Date: | July 2015 |
Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma
This study will evaluate the prevalence of geriatric syndromes in older adults with multiple
myeloma, examine relationships between baseline geriatrics syndromes and initial treatment
selection, and examine risk of functional decline.
Relationship between baseline geriatric questionnaires and initial treatment selection in
older adults with newly diagnosed multiple myeloma.
Feasibility of subjects completing the CARG geriatric assessments at baseline, 3 months and
6 months.
Comorbidities or dependence in IADLs at baseline predict decline in functional status at 6
months of follow-up in older adults with newly diagnosed multiple myeloma.
myeloma, examine relationships between baseline geriatrics syndromes and initial treatment
selection, and examine risk of functional decline.
Relationship between baseline geriatric questionnaires and initial treatment selection in
older adults with newly diagnosed multiple myeloma.
Feasibility of subjects completing the CARG geriatric assessments at baseline, 3 months and
6 months.
Comorbidities or dependence in IADLs at baseline predict decline in functional status at 6
months of follow-up in older adults with newly diagnosed multiple myeloma.
Inclusion Criteria:
- Patient must have a diagnosis of multiple myeloma by IMWF criteria: diagnosis must
have occurred within 3 months of study enrollment.
- Patient must be ≥ 65 years of age.
- Patient's life expectancy must be ≥ 6 months.
- Patient must be willing to complete follow-up assessments.
- Patient must be able to understand and willing to sign a written informed consent
document.
Exclusion Criteria:
- Patient must not have a diagnosis of smoldering myeloma.
- Patient must not have concomitant amyloidosis.
We found this trial at
1
site
Click here to add this to my saved trials
